Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Diana Paola Arteaga"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Susan M. Armstrong, Danny Ghazarian, Thiago Pimentel Muniz, Ian F. G. King, Zaid Saeed Kamil, Kendra Ross, Samuel D. Saibil, David Hogg, Anna Spreafico, Marcus O. Butler, Deirdre Kelly, April A.N. Rose, Diana Paola Arteaga
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
PurposeAnti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4c40352e051bdc9aefc2783362b190
http://europepmc.org/articles/PMC7831745
http://europepmc.org/articles/PMC7831745
1043P NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma
Autor:
L. Mantle, R. Singh, A. Covelli, T. Pimentel Muniz, Sofia Genta, Diana Paola Arteaga, Alexandra M. Easson, Ian F. G. King, Z. Saeed Kamil, A. Rose, Marcus O. Butler, Anna Spreafico, Samuel Saibil, M. Vilbert, David W. Hogg
Publikováno v:
Annals of Oncology. 32:S874
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cfce072843fcf6fe3b881cdf15a37d8
https://doi.org/10.1016/j.annonc.2021.08.1428
https://doi.org/10.1016/j.annonc.2021.08.1428
Autor:
Diana Paola Arteaga, David Hogg, Maysa Tamara Silveira Vilbert Pereira, Samuel Saibil, Raviya Singh, Marcus O. Butler, Luke Mantle, Hadee Lone, Sofia Genta, Diana Gray, Thiago Pimentel Muniz, Anna Spreafico
Publikováno v:
Journal of Clinical Oncology. 39:9557-9557
9557 Background: Melanoma has a high probability of central nervous system (CNS) spread. Although first line nivolumab and ipilimumab resulted in 56% response rate and 29.2 months median overall survival (OS) in patients with melanoma brain metastase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d5276fe0546c8c61de8cb68ee6bbf10
https://doi.org/10.1200/jco.2021.39.15_suppl.9557
https://doi.org/10.1200/jco.2021.39.15_suppl.9557
Autor:
Tracy Stockley, David Hogg, Anna Spreafico, Samuel Saibil, Ian King, Diana Paola Arteaga, Marcus O. Butler, Zaid Saeed Kamil, Diana Gray, Diane Liu, Thiago Pimentel Muniz
Publikováno v:
Journal of Clinical Oncology. 39:e21575-e21575
e21575 Background: Targeted therapy with BRAF and MEK inhibitors constitute part of the standard treatment for BRAF V600 mutated melanoma. Timely detection of BRAF mutation is necessary for clinicians and patients to make treatment decisions. We aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd7b25197507399e1d69abb12e839854
https://doi.org/10.1200/jco.2021.39.15_suppl.e21575
https://doi.org/10.1200/jco.2021.39.15_suppl.e21575